Mechanisms of β-lactam Resistance Among Pseudomonas aeruginosa
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Treatment of serious P. aeruginosa infections becomes more challenging with each passing year. As this pathogen acquires more transferrable resistance mechanisms and continues to rapidly adapt and emerge resistant during the course of antimicrobial therapy, we face the growing threat of pan-resistance. This review has focused on those mechanisms that directly impact the future of β-lactam antibiotics, including the production of β-lactamases, porin-mediated resistance, and/or the overexpression of RND efflux pumps. With the pipeline of new anti-pseudomonal agents diminishing, it is essential that novel therapeutic strategies be explored. These include targeting biofilm formation and maintenance, virulence factors, and resistance mechanisms. Furthermore, we must continue to search for effective antibacterial combinations to not only prevent further emergence of resistance but also treat resistant strains already in the environment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Updated Functional Classification of β-Lactamases
Bush, K., & Jacoby, G. A. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01009-09 · Cited by 2,367
Growing Group of Extended-Spectrum β-Lactamases: the CTX-M Enzymes
Bonnet, R. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.1.1-14.2004 · Cited by 1,494
Overview of Nosocomial Infections Caused by Gram-Negative Bacilli
Weinstein, R. A., Gaynes, R., Edwards, J. R., & System, N. N. I. S. (2005) · Clinical Infectious Diseases · doi:10.1086/432803 · Cited by 1,404
β-Lactamases of Kluyvera ascorbata , Probable Progenitors of Some Plasmid-Encoded CTX-M Types
Humeniuk, C., Arlet, G., Gautier, V., Grimont, P., Labia, R., & Philippon, A. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.9.3045-3049.2002 · Cited by 338
Function of Pseudomonas Porins in Uptake and Efflux
Hancock, R. E. W., & Brinkman, F. S. L. (2002) · Annual Review of Microbiology · doi:10.1146/annurev.micro.56.012302.160310 · Cited by 319
Efflux-Mediated Resistance to Tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1
Dean, C. R., Visalli, M. A., Projan, S. J., Sum, P.-E., & Bradford, P. A. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.3.972-978.2003 · Cited by 286
Failure of Therapy in Pseudomonas Endocarditis: Selection of Resistant Mutants
Jimenez-Lucho, V. E., Saravolatz, L. D., Medeiros, A. A., & Pohlod, D. (1986) · Journal of Infectious Diseases · doi:10.1093/infdis/154.1.64 · Cited by 36
Cited by
Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies
Pang, Z., Raudonis, R., Glick, B. R., Lin, T.-J., & Cheng, Z. (2019) · Biotechnology Advances · doi:10.1016/j.biotechadv.2018.11.013 · Cited by 2,306
Tamma, P. D., Aitken, S. L., Bonomo, R. A., Mathers, A. J., van Duin, D., & Clancy, C. J. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad428 · Cited by 740
Tamma, P. D., Aitken, S. L., Bonomo, R. A., Mathers, A. J., van Duin, D., & Clancy, C. J. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac268 · Cited by 526
Verdial, C., Serrano, I., Tavares, L., Gil, S., & Oliveira, M. (2023) · Biomedicines · doi:10.3390/biomedicines11041221 · Cited by 71
Metadata
- Authors
- J. Wolter, D., & D. Lister, P.
- Venue
- Current Pharmaceutical Design
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2013-01-01
- Volume
- 19
- Issue
- 2
- Pages
- 209-222
- ISSN
- 1381-6128 (ISSN-L)
- OpenAlex
- W1989035014
- Cited by
- 72
- References
- 7
- FWCI
- 1.22
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mechanisms of β-lactam Resistance Among Pseudomonas aeruginosa. https://app.cochat.ai/papers/10.2174/138161213804070311
- The paper
- J. Wolter, D., & D. Lister, P. (2013). Mechanisms of β-lactam Resistance Among Pseudomonas aeruginosa. Current Pharmaceutical Design. https://doi.org/10.2174/138161213804070311
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.